Our Expert Network

1. Inside The mRNA–LNP Patent Wars: A Q&A With Goodwin On Litigation, Strategy, And What Comes Next 3/16/2026

   Patent disputes around mRNA constructs and LNP delivery are intensifying. Goodwin’s Natasha Daughtrey and Bill Christiansen unpack litigation trends, IP strategy, and what RNA developers should expect next.

2. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

   Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

3. Dual Centrifugation And The Next Phase Of Lipid Nanoparticle Development 3/9/2026

   Dual centrifugation enables rapid, small-scale LNP screening with high encapsulation, reproducibility, and preserved RNA integrity — offering a flexible bridge between benchtop discovery and scalable manufacturing.

4. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

   Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

5. Proteomics Tools: A Resurrection 3/4/2026

   For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

6. Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit 3/3/2026

   Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.

7. Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage 3/2/2026

   Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.

8. The Evolution Of Oligonucleotide Manufacturing: Engineering Considerations For Scale, Efficiency, And Facility Design 2/27/2026

   As oligos move toward larger indications, manufacturing shifts from chemistry alone to facility design—balancing scale, solvent safety, cost, and flexibility as SPOS, slurry, and enzymatic paths converge.

9. Targeted Delivery – A Holy Grail For CRISPR Gene Editing 2/26/2026

   Precise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.

10. The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety 2/25/2026

    Why LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.